Facebook Linkedin RSS Twitter Youtube
Home 2021

Enzyme therapy

Gene Therapy for ADA-SCID Still Benefitting Patients after Two to Three Years
Genome Editing

Gene Therapy for ADA-SCID Still Benefitting Patients after Two to Three Years

Kevin Mayer -
0
Sangamo Shares Plunge after Interim Results for MPS Candidates Fall Short of Clinical Benefit
Featured

Sangamo Shares Plunge after Interim Results for MPS Candidates Fall Short of Clinical Benefit

Alex Philippidis -
0
Gene Therapy for Rare Diseases
Insights

Gene Therapy for Rare Diseases

Sue Pearson -
0
FDA Approves Ultragenyx Enzyme Replacement Therapy for MPS VII
Industry News

FDA Approves Ultragenyx Enzyme Replacement Therapy for MPS VII

GEN Staff Writer -
0
Nestlé Health Science, Codexis to Develop PKU Enzyme in Protein Platform Partnership
Bioprocessing

Nestlé Health Science, Codexis to Develop PKU Enzyme in Protein Platform Partnership

GEN Staff Writer -
0
Erytech, Queen’s Partner to Develop Red Blood Cell-Encapsulated Enzyme Therapy
Drug Discovery

Erytech, Queen’s Partner to Develop Red Blood Cell-Encapsulated Enzyme Therapy

GEN Staff Writer -
0
Rubius Therapeutics Closes $120M Financing, Plans Trials Next Year
Cancer

Rubius Therapeutics Closes $120M Financing, Plans Trials Next Year

GEN Staff Writer -
0
Revolutionizing Biotechnology with Artificial Restriction Enzymes
Genome Editing

Revolutionizing Biotechnology with Artificial Restriction Enzymes

GEN Staff Writer -
0
mRNA: Addressing the Blind Spot of Enzyme Replacement Therapy
Insights

mRNA: Addressing the Blind Spot of Enzyme Replacement Therapy

Michael Houston -
0
Protalix Sells Share of ELELYSO Collaboration, Equity Stake to Pfizer
Drug Discovery

Protalix Sells Share of ELELYSO Collaboration, Equity Stake to Pfizer

GEN Staff Writer -
0
123...5Page 1 of 5
Copyright © 2023 Genetic Engineering & Biotechnology News. All Rights Reserved.